Condition

Non-Alcoholic Fatty Liver Disease

ClinicalTrials.gov condition label

Clinical trials115

Recruiting17

Common interventions25

Lead sponsors shown15

Clinical trials

60 shown

Effect of Insulin Lowering on LipogenesisNCT07403604 · 2026-07-01

Additive Efficacy of Physical Activity Program in Hypthyroidism Elder Females With Glaucoma and Fatty Liver IssuesNCT07599241 · 2026-03-15

Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled TrialNCT06138821 · 2025-06-24

Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)NCT06571474 · 2024-08-01

Fibrosis Lessens After Metabolic SurgeryNCT06374875 · 2024-07-11

Human Models of Selective Insulin Resistance: Alpelisib, Part INCT06354088 · 2024-04-24

Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLDNCT06704321 · 2024-01-31

Effect of Timed-Restricted Eating on Metabolic HealthNCT06061042 · 2023-10-01

Comorbidities Resolution After MGB Surgery and Change in Body CompositionNCT06015620 · 2023-09-01

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for CancerNCT05463796 · 2023-04-25

Quantifying Hepatic Mitochondrial Fluxes in HumansNCT05305287 · 2022-11-01

Intermittent Fasting for NAFLD in AdultsNCT04899102 · 2022-02-01

Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver DiseaseNCT05728697 · 2021-06-01

Change of Adipose Tissues and Triglyceride After Bariatric Surgery or Life-style InterventionNCT03875625 · 2019-04-01

Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes After New Onset of STEMINCT05046483 · 2018-12-30

Prognostic Significance of Fatty Liver Disease in Bariatric PatientsNCT03535142 · 2018-08-15

European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD)NCT04190849 · 2017-11-14

Human Models of Selective Insulin Resistance: Pancreatic ClampNCT06558422 · 2027-01-01

NOT_YET_RECRUITING

Lifestyle, Dietary Patterns, and Cardiometabolic Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease Among People Living With HIVNCT07861594 · 2026-11-01

NOT_YET_RECRUITING

Treatment and Handling Severe Obesity-Related Comorbidities in Adolescents Through ExerciseNCT06520800 · 2025-01-01

NOT_YET_RECRUITING

Dexamethasone/Pancreatic Clamp P&FNCT06126354 · 2024-07-01

The Gut, Liver And Metabolome in Human Immunodeficiency Virus and Non Alcoholic Fatty Liver DiseaseNCT06113003 · 2024-04-18

ACTIVE_NOT_RECRUITING

Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 DiabetesNCT07269197 · 2024-03-22

Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver DiseaseNCT06218342 · 2024-02-15

Direct Versus Indirect Effect of Amino Acids on HepatokinesNCT06240039 · 2024-02-11

ACTIVE_NOT_RECRUITING

The Metabolic Impact of Intermittent Carbohydrate Restriction in Individuals With Type 2 DiabetesNCT06144593 · 2024-01-03

The Effect of GLP-1 Analogues on Liver Steatosis and Fibrosis in Diabetic and Obese Patients in a Clinical SettingNCT07021443 · 2023-10-09

Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 AnalogueNCT05751720 · 2023-10-01

Smart Watch Insights for Prevention of Exacerbations and Enhance Rehabilitation - Movement StudyNCT06011356 · 2023-08-30

ACTIVE_NOT_RECRUITING

Pancreatic Clamp in NAFLDNCT05724134 · 2023-08-29

Glycemic Effect of Diazoxide in NAFLDNCT05729282 · 2023-08-01

Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DMNCT06005012 · 2023-07-25

ACTIVE_NOT_RECRUITING

Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver DiseaseNCT05067621 · 2023-07-17

ACTIVE_NOT_RECRUITING

Diet, Immunometabolism and Non-alcoholic Fatty Liver DiseaseNCT05968378 · 2023-06-01

Probiotic Lysate (Postbiotic and Metabiotic) Supplementation for Adults NAFLD Patients (DELI_NAFLD Study)NCT05804422 · 2023-05-01

Effect of a Multi-ingredient on Visceral Adiposity and Non-alcoholic Fatty Liver Disease in Individuals With Abdominal ObesityNCT05807204 · 2023-05-01

Optimal Exercise Frequency to Reduce Liver Fat in Centrally Obese Adults With Non-Alcoholic Fatty Liver DiseaseNCT05741957 · 2023-03-02

ACTIVE_NOT_RECRUITING

Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes MellitusNCT05779644 · 2023-02-23

Effects of Mindfulness Based Stress Reduction Intervention in Patients With Non-alcoholic Fatty Liver DiseaseNCT05130346 · 2023-02-01

Multi-morbidity Screening in People With Type 2 Diabetes and Pre DiabetesNCT06053177 · 2023-01-25

ACTIVE_NOT_RECRUITING

Beneficial Effects of Dietary and Lifestyle Change in Overweight and Obese SubjectsNCT05447351 · 2023-01-01

SRMA of the Effect of Soy Milk vs Cow's Milk on Cardiometabolic OutcomesNCT05637866 · 2022-10-01

Clinical Epidemiology of NAFLD in Children and AdolescentsNCT05526274 · 2022-10-01

MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and HypertriglyceridemiaNCT05464784 · 2022-08-22

ACTIVE_NOT_RECRUITING

A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASHNCT03970031 · 2022-06-01

Healthy Liver - Healthy BrainNCT05216796 · 2022-05-18

Moderately Carbohydrate-restricted Diet to Treat NAFLD in AdolescentsNCT05268042 · 2022-05-01

Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)NCT05292911 · 2022-03-09

Effect of Adjustable Intragastric Balloon in Obese Non-alcoholic Fatty Liver DiseaseNCT04182646 · 2022-02-25

Identification and Characterization of NAFLD in TurkeyNCT05194553 · 2022-02-15

Microbiome-Mediated Gut Dysfunction in Non-Alcoholic Fatty Liver DiseaseNCT05209100 · 2022-02-11

Intermittent Fasting Versus Diet to Stop Hypertension on Metabolic Risk Profile in Nonalcoholic Fatty Liver PatientsNCT06666894 · 2022-01-01

Non-Alcoholic Fatty Liver Disease and Anthropometric MeasurementsNCT05810506 · 2021-10-01

ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)NCT05006885 · 2021-09-30

Ectopic Fat in Singaporean Women - the Culprit Leading to Gestational Diabetes, Metabolic Syndrome, and Type 2 Diabetes (TANGO Study)NCT05259475 · 2021-08-20

Effect of F. Prausnitzii on Glycemic ControlNCT04938843 · 2021-08-16

Development and Evaluation of a Glucagon Sensitivity Test in Individuals With and Without Hepatic SteatosisNCT04907721 · 2021-05-27

NAFLD Primary CareNCT04918732 · 2021-05-05

Effect of L-Citrulline Supplementation on NAFLD in Adolescents With ObesityNCT04871360 · 2021-05-05

Effects of High-Intensity Interval Training Exercise in Adolescents With HepatosteatosisNCT04342390 · 2021-04-02

Common interventions

Leading sponsors

Columbia University6 Steno Diabetes Center Copenhagen3 Altimmune, Inc.2 Cairo University2 Copenhagen University Hospital, Rigshospitalet2 Maastricht University2 Maastricht University Medical Center2 Massachusetts General Hospital2 The University of Hong Kong2 University Hospital, Gentofte, Copenhagen2 University of Copenhagen2 University of Oxford2 University of Toronto2 Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)1 AdventHealth Translational Research Institute1

Trial status mix

COMPLETED53

UNKNOWN26

RECRUITING17

ACTIVE_NOT_RECRUITING9

TERMINATED4

NOT_YET_RECRUITING3

WITHDRAWN3

Phase mix

NA55

PHASE110

PHASE28

PHASE47

EARLY_PHASE11

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.